PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för givinostat. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

29 hits

Bibliografisk träff 2024-04-01

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, Müller-Felber W, Niks EH, Schara-Schmidt U, Bertini E, Comi GP, Mathews KD, Servais L, Vandenborne K, Johannsen J, Messina S, Spinty S, McAdam L, Selby K, Byrne B, Laverty CG, Carroll K, Zardi G, Cazzaniga S, Coceani N, Bettica P, McDonald CM, EPIDYS Study Group.

Lancet Neurol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(24)00036-x

Bibliografisk träff 2024-03-01

ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells.

Lim RR, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W, Kim JE, Barathi VA, Ghosh A, Chaurasia SS.

FASEB J · research-article; journal article; research support, n.i.h., extramural · DOI 10.1096/fj.202301592r

Bibliografisk träff 2024-02-14

Dual-Epigenetically Relieving the MYC-Correlated Immunosuppression via an Advanced Nano-Radiosensitizer Potentiates Cancer Immuno-Radiotherapy.

Wang G, Yan J, Tian H, Li B, Yu X, Feng Y, Li W, Zhou S, Dai Y.

Adv Mater · journal article · DOI 10.1002/adma.202312588

Bibliografisk träff 2024-02-07

In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients.

Tosca EM, De Carlo A, Bartolucci R, Fiorentini F, Di Tollo S, Caserini M, Rocchetti M, Bettica P, Magni P.

CPT Pharmacometrics Syst Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/psp4.13087

Bibliografisk träff 2023-09-28

Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.

Zichittella C, Loria M, Celesia A, Di Liberto D, Corrado C, Alessandro R, Emanuele S, Conigliaro A.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2023.1275833

Bibliografisk träff 2023-05-23

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).

Celesia A, Franzò M, Di Liberto D, Lauricella M, Carlisi D, D'Anneo A, Notaro A, Allegra M, Giuliano M, Emanuele S.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms24119148

Bibliografisk träff 2023-04-01

Population pharmacokinetic-pharmacodynamic analysis of givinostat.

Fiorentini F, Germani M, Del Bene F, Pellizzoni C, Cazzaniga S, Rocchetti M, Bettica P.

Expert Opin Drug Metab Toxicol · clinical trial, phase ii; journal article · DOI 10.1080/17425255.2023.2219839

Bibliografisk träff 2023-03-01

Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.

Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Kitanaka C, Okada M.

Anticancer Res · journal article · DOI 10.21873/anticanres.16258

Bibliografisk träff 2023-02-15

HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.

Cui J, Xu F, Bai W, Zhao T, Hong J, Zuo W.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-023-03973-3

Bibliografisk träff 2023-01-30

Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study.

Comi GP, Niks EH, Vandenborne K, Cinnante CM, Kan HE, Willcocks RJ, Velardo D, Magri F, Ripolone M, van Benthem JJ, van de Velde NM, Nava S, Ambrosoli L, Cazzaniga S, Bettica PU.

Front Neurol · research-article; journal article · DOI 10.3389/fneur.2023.1095121

Bibliografisk träff 2022-11-29

ITF2357 induces cell cycle arrest and apoptosis of meningioma cells via the PI3K-Akt pathway.

Zhang L, Li C, Marhaba Aziz, Zhu R, Jiapaer Z.

Med Oncol · journal article · DOI 10.1007/s12032-022-01883-w

Bibliografisk träff 2022-11-17

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.

Anichini A, Molla A, Nicolini G, Perotti VE, Sgambelluri F, Covre A, Fazio C, Lofiego MF, Di Giacomo AM, Coral S, Manca A, Sini MC, Pisano M, Noviello T, Caruso F, Brich S, Pruneri G, Maurichi A, Santinami M, Ceccarelli M, Palmieri G, Maio M, Mortarini R, EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators.

J Exp Clin Cancer Res · research-article; journal article · DOI 10.1186/s13046-022-02529-5

Bibliografisk träff 2022-09-15

Acute Kidney Injury and Diastolic Dysfunction: Opportunity for Targeted Intervention?

Soranno DE, Gist KM.

Nephron · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1159/000526010

Bibliografisk träff 2022-08-17

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis.

Celesia A, Notaro A, Franzò M, Lauricella M, D'Anneo A, Carlisi D, Giuliano M, Emanuele S.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines10081994

Bibliografisk träff 2022-07-27

Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage.

Pawelec P, Sypecka J, Zalewska T, Ziemka-Nalecz M.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms23158287

Bibliografisk träff 2022-07-22

Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model.

Dibekoğlu C, Erbaş O, Erbaş O.

Acta Cir Bras · research-article; journal article · DOI 10.1590/acb370503

Bibliografisk träff 2022-06-16

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics.

Taiarol L, Bigogno C, Sesana S, Kravicz M, Viale F, Pozzi E, Monza L, Carozzi VA, Meregalli C, Valtorta S, Moresco RM, Koch M, Barbugian F, Russo L, Dondio G, Steinkühler C, Re F.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers14122978

Bibliografisk träff 2022-04-27

Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination.

Hoch L, Bourg N, Degrugillier F, Bruge C, Benabides M, Pellier E, Tournois J, Mahé G, Maignan N, Dawe J, Georges M, Papazian D, Subramanian N, Simon S, Fanen P, Delevoye C, Richard I, Nissan X.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2022.856804

Bibliografisk träff 2021-08-02

Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.

Huang HM, Fan SJ, Zhou XR, Liu YJ, Li X, Liao LP, Huang J, Shi CC, Yu L, Fu R, Fan JG, Zhang YY, Luo C, Li GM.

Acta Pharmacol Sin · research-article; journal article · DOI 10.1038/s41401-021-00725-1

Bibliografisk träff 2021-06-29

Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy.

Giovarelli M, Zecchini S, Catarinella G, Moscheni C, Sartori P, Barbieri C, Roux-Biejat P, Napoli A, Vantaggiato C, Cervia D, Perrotta C, Clementi E, Latella L, De Palma C.

Pharmacol Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.phrs.2021.105751

Bibliografisk träff 2021-06-01

Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation.

Yafei J, Haoran M, Wenyan J, Linghang X, Kai T, Gangyang W, Zhuoying W, Jing H, Mengkai Y, Yujie T, Yingqi H, Zhengdong C.

J Orthop Translat · research-article; journal article · DOI 10.1016/j.jot.2021.04.004

Bibliografisk träff 2021-03-08

HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling.

Travers JG, Wennersten SA, Peña B, Bagchi RA, Smith HE, Hirsch RA, Vanderlinden LA, Lin YH, Dobrinskikh E, Demos-Davies KM, Cavasin MA, Mestroni L, Steinkühler C, Lin CY, Houser SR, Woulfe KC, Lam MPY, McKinsey TA.

Circulation · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1161/circulationaha.120.046462

Bibliografisk träff 2020-06-01

Givinostat: an emerging treatment for polycythemia vera.

Chifotides HT, Bose P, Verstovsek S.

Expert Opin Investig Drugs · comparative study; research-article; review; journal article · DOI 10.1080/13543784.2020.1761323

Bibliografisk träff 2019-12-02

Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.

Osko JD, Christianson DW.

Biochemistry · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.biochem.9b00934

Bibliografisk träff 2019-09-01

Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C.

J Cancer Res Clin Oncol · published erratum; correction; journal article · DOI 10.1007/s00432-019-02980-6

Bibliografisk träff 2018-11-24

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C.

J Cancer Res Clin Oncol · research-article; journal article · DOI 10.1007/s00432-018-2800-8

Bibliografisk träff 2016-10-27

Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells.

Angeletti F, Fossati G, Pattarozzi A, Würth R, Solari A, Daga A, Masiello I, Barbieri F, Florio T, Comincini S.

Front Mol Neurosci · research-article; journal article · DOI 10.3389/fnmol.2016.00107

Bibliografisk träff 2012-05-01

[ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].

Yu WJ, Wang L, You LS, Mei C, Ma QL, Jin J.

Zhonghua Xue Ye Xue Za Zhi · research support, u.s. gov't, non-p.h.s.; journal article; english abstract

Bibliografisk träff 2010-06-15

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.

Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1111/j.1365-2141.2010.08266.x